Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT02715258
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT02715258
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02715258. Randomized; quadruple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2017-04 (actual). Results posted on 2021-04-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct02715258- Content hash
866b96f3570faf70a4464887e19ad9767499698976f8ae4c5ff5fea70e4ab508